Navigation Links
Sharps Compliance Corp. Reports Second Quarter Fiscal 2009 Results

- Awarded $40 million, five-year U.S. Government contract; $28.5 million in contract year one

- Medical Waste Management solutions for pharmaceutical manufacturing industry drives revenue for first half

- Earnings per share quadruple on $1.8 million income tax benefit

- Strong balance sheet with $2.1 million in cash, stockholders' equity growth of 134% and no debt

HOUSTON, Feb. 10 /PRNewswire-FirstCall/ -- Sharps Compliance Corp. (OTC Bulletin Board: SCOM) ("Sharps" or the "Company"), a leading provider of cost-effective disposal solutions for alternative site healthcare customers and other generators of medical waste, today reported revenue of $3.4 million in the second quarter of fiscal 2009, which ended December 31, 2008, a $381 thousand decrease compared with the second quarter of fiscal 2008. Customer billings, which the Company believes is an appropriate measure of performance and progress of the business, decreased 14.4% to $3.2 million for the second quarter of fiscal 2009, compared with $3.8 million in the same period the prior fiscal year. The decrease in revenue and customer billings for the quarter is primarily due to timing associated with the vendor management inventory programs the Company provides to pharmaceutical manufacturers. For the six-month period ended December 31, 2008, revenue increased $497 thousand to $7.6 million, compared with the first six months of fiscal 2008. Year-to-date customer billings were $7.9 million in fiscal 2009 and $7.4 million in fiscal 2008, an increase of 7.2%. The increase in year-to-date revenue and customer billings was primarily driven by strong growth in the pharmaceutical, retail and professional markets.

Dr. Burton J. Kunik, Chairman and Chief Executive Officer of Sharps Compliance, commented, "Our efforts to move from being a provider of products and services to a comprehensive solutions provider of medical waste management systems is being realized by our recent pharmaceutical and government contracts. Although this last quarter does not demonstrate our earnings power, with the addition of our government contract and continued growth in the pharmaceutical manufacturing business, we believe consolidated gross margins could exceed 50% beginning in the fourth quarter of fiscal year 2009 ending June 30, 2009."

$40 million U.S. Government Contract Award

The Company recently announced it had been awarded a contract to provide its Sharps Medical Waste Management System ("Sharps(R)MWMS(TM)") to an agency of the United States Government.

The total contract is valued at approximately $40 million and is expected to be executed over a five year period. The Company has received a purchase order for $28.5 million which represents product and services to be provided during the first contract year. The following four option years represent payment for program maintenance.

Sales and Billings Growth

Customer billings from contracts with pharmaceutical manufacturers increased to $1.0 million in the six-months ended December 31, 2008 compared with $498 thousand in the same period the prior year. The recently announced renewal of the Company's first vendor managed inventory program for a top ten pharmaceutical manufacturer's patient support program contributed approximately $700 thousand in billings in the first quarter of fiscal 2009 and is expected to generate an additional $900 thousand in billings during the fourth quarter of fiscal 2009 ending June 30, 2009. Billings to additional pharmaceutical manufacturers contributed approximately $300 thousand to the quarter ended December 31, 2008.

Sharps' vendor managed inventory program includes the direct fulfillment of the Sharps Disposal By Mail System(R) to the pharmaceutical manufacturers' self-injecting patient support program participants, who use the product as a convenient means of disposing of used syringes. Sharp's proprietary SharpsTracer(TM) system tracks the return of the Sharps Disposal By Mail System(R) by the patient to the treatment facility, where the package is scanned and weighed prior to destruction. This data is electronically transmitted to the pharmaceutical manufacturer which assists them in monitoring drug usage and provides them with a touch point for individual patient follow-up.

Customer billings to retail market customers increased 29.5% to $1.3 million in the first half of fiscal 2009 as a result of strong seasonal demand for the Sharps Disposal By Mail Systems(R) as pharmacies and clinics in retail settings administer flu shots to their customers. Higher customer billings to the professional and commercial markets were offset by decreased billings to healthcare and hospitality customers.

Second Quarter Fiscal 2009 Operating Performance

Gross margin was 38.2% in the second quarter of fiscal 2009 and 41.1% for the fiscal year-to-date period ended December 31, 2008. Gross margins for the quarter were adversely impacted by the effect of lower revenue, increased operations infrastructure costs as the Company prepared for higher volume including that related to the recent $40 million U.S. Government contract and the mix of product sold (i.e., lower percentage of higher margin mailback business). For the fiscal year-to-date period, gross margins were down from the prior year as a result of approximately $200 thousand in excess air freight shipping costs that were incurred in the first quarter ended September 30, 2008 to address supply and manufacturing issues associated with the Company's Pitch-It IV Poles and increased operations infrastructure costs as the Company prepared for the higher volume including that related to the recent U.S. Government contract.

Selling, general and administrative (SG&A) expense was $1.4 million for the second quarter of fiscal year 2009, an increase of $253 thousand, or 21% over the corresponding period of the prior year. For the six-months ended December 31, 2008, SG&A expense was $2.6 million compared with $2.3 million for the corresponding period of the prior year, an increase of 11%. The increase in the SG&A for both the second quarter and fiscal year-to-date periods was a result of increased non-cash 123R stock-based compensation expense, professional fees, recruiting and compensation-related expenses.

Dr. Kunik continued, "We invested heavily in our organization as we developed the systems and processes necessary to address the expected and rapid increase in top line growth. The operating leverage inherent in our business model will become even more evident as the Company's top line grows significantly while our SG&A expense increases at a much lower pace."

Operating loss for the second quarter of fiscal 2009 was $232 thousand, compared with operating income of $354 thousand in the second quarter of fiscal 2008. Operating income for the six-months ended December 31, 2008 was $377 thousand, or 5% of sales, a decrease of $198 thousand compared with operating income of $575 thousand, or 8% of sales, in the same period the prior fiscal year period. The reduction in operating income was primarily due to the increases in SG&A, as noted above.

During the quarter ended December 31, 2008, the Company evaluated its deferred tax asset valuation allowance and determined that such valuation allowance should be reduced to zero. As a result of this decision, the Company's balance sheet reflects deferred tax assets of $3.1 million at December 31, 2008. Additionally, the Company recorded a corresponding income tax benefit of $1.8 million, or $0.13 per diluted share, and an increase to additional paid in capital of $1.3 million during the quarter ended December 31, 2008.

Net income was $1.6 million, or $0.11 per diluted share, for the second quarter of fiscal 2009 compared with net income of $380 thousand, or $0.03 per diluted share, in the second quarter of fiscal 2008. Net income was $2.2 million, or $0.16 per diluted share, for the six months ended December 31, 2008 compared with net income of $622 thousand, or $0.05 per diluted share, in the corresponding period of prior fiscal year.

Liquidity and Balance Sheet Strength

Cash and cash equivalents were $2.1 million at December 31, 2008, up from $2.0 million at June 30, 2008. At December 31, 2008, stockholders' equity and total assets were $6.8 million and $9.5 million, respectively, up from $2.9 million and $5.7 million at June 30, 2008, respectively. Although Sharps maintains a $2.5 million line of credit with JPMorgan Chase (the "Bank"), no amounts were outstanding at June 30, 2008. The line of credit is available to finance working capital, expansion and/or potential acquisition opportunities. The Company has completed negotiations and received a favorable term sheet from the Bank to increase its line of credit from $2.5 to $4.5 million. While no assurances can be made, the Company believes it should have its new line of credit in place by the end of February 2009.

Dr. Kunik concluded, "Over the last two years we have been able to grow shareholder equity over 520% and established a solid balance sheet to a level that qualifies us to move from the bulletin board and apply for listing on a major exchange. We are confident that we have the experience, expertise, personnel and infrastructure to transform into a comprehensive provider of medical waste management services for alternative site healthcare customers and other generators of medical waste."

Second Quarter 2009 Webcast and Conference Call

The Company will host a teleconference today beginning at 1:00 p.m. Eastern Time. During the teleconference, Dr. Burton J. Kunik, Chairman and Chief Executive Officer, and David P. Tusa, Executive Vice President and Chief Financial Officer, will review the financial and operating results for the period and discuss Sharps' corporate strategy and outlook. A question-and-answer session will follow.

The Sharps conference call may be accessed the following ways:

  • The live webcast may be found at Participants should go to the website 10 - 15 minutes prior to the scheduled conference in order to register and download any necessary audio software. Webcast listeners will have the opportunity to submit questions to the speakers (verbal or via e-mail). Select questions will be summarized and addressed during the question-and-answer portion of the call.
  • The teleconference may also be accessed by dialing (201) 689-8560 and requesting conference ID number 311150, approximately 5 - 10 minutes prior to the call.

To listen to the archived call:

  • The archived webcast will be at A transcript will also be posted once available.
  • A replay may also be heard by calling (201) 612-7415, and entering account number 3055 and conference ID number 311150.

The telephonic replay will be available from 4:00 p.m. Eastern Time the day of the teleconference until 11:59 p.m. Eastern Time on Tuesday, February 17, 2009.

About Sharps Compliance Corp.

Headquartered in Houston, Texas, Sharps Compliance is a leading provider of cost-effective disposal solutions for alternative site healthcare facilities and other generators of medical waste and unused pharmaceuticals. The Company's flagship product, the Sharps Disposal by Mail System(R), is a cost-effective and easy-to-use solution to dispose of medical waste such as hypodermic needles, lancets and any other medical device or objects used to puncture or lacerate the skin (referred to as "sharps").

The Sharps(R)MWMS(TM), a Medical Waste Management System, is a comprehensive medical waste solution which includes an array of services and products necessary to effectively collect, store and dispose of medical waste in the alternate site market (i.e., outside of the hospital or large healthcare facility setting). The System, which is designed for rapid deployment, features the Sharps Disposal By Mail System(R) products combined with warehousing, inventory management, training, data and other services necessary to provide a comprehensive solution. The Sharps(R)MWMS(TM) is designed to be an integral part of governmental and commercial emergency preparedness programs.

The Company also offers a number of products specifically designed for the home healthcare market and products for the safe disposal of unused pharmaceuticals, RxTakeAway(TM). Sharps Compliance focuses on targeted growth markets such as the pharmaceutical, retail, commercial, and hospitality markets, as well as serving a variety of additional markets. Sharps is a leading proponent and participant in the development of public awareness and solutions for the safe disposal of needles, syringes and other sharps in the community setting.

As a fully integrated manufacturer providing customer solutions and services, Sharps Compliance's solid business model, with strong margins and significant operating leverage, and early penetration into emerging markets, uniquely positions the company for strong future growth.

More information on Sharps Compliance can be found on its website at:

Safe Harbor Statement

The information made available in this press release contains certain forward-looking statements which reflect Sharps Compliance Corp.'s current view of future events and financial performance. Wherever used, the words "estimate", "expect", "plan", "anticipate", "believe", "may" and similar expressions identify forward-looking statements. Any such forward-looking statements are subject to risks and uncertainties and the company's future results of operations could differ materially from historical results or current expectations. Some of these risks include, without limitation, the company's ability to educate its customers, development of public awareness programs to educate the identified consumer, customer preferences, the Company's ability to scale the business and manage its growth, the degree of success the Company has at gaining more large customer contracts, managing regulatory compliance and/or other factors that may be described in the company's annual report on Form 10-K, quarterly reports on Form 10-Q and/or other filings with the Securities and Exchange Commission. Future economic and industry trends that could potentially impact revenues and profitability are difficult to predict. The company assumes no obligation to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results express or implied therein will not be realized.

    For more information contact:            - OR -
    David P. Tusa                            Deborah Pawlowski
    Executive Vice President, Chief          Kei Advisors LLC
    Financial Officer & Business             Investor Relations
    Development                              Phone: (716) 843-3908
    Phone: (713) 660-3514                    Email:


                          Consolidated Statements of Income

                         Three-Months                   Six-Months
                            Ended                          Ended
                         December 31,                   December 31,
                         ------------                   ------------
                                             %                             %
                        2008       2007   Change       2008       2007  Change
                        ----       ----                ----       ----

    Revenue       $3,369,646 $3,750,802  (10.2%) $7,639,182 $7,141,914   7.0%

      Cost of
       revenue     2,081,422  2,145,468   (3.0%)  4,501,783  4,103,203   9.7%
                   ---------  ---------           ---------  ---------
      Gross profit 1,288,224  1,605,334  (19.8%)  3,137,399  3,038,711   3.2%
         margin        38.2%      42.8%               41.1%      42.5%
       expense     1,438,016  1,185,046   21.3%   2,600,971  2,340,427  11.1%
       amortization   82,854     65,920   25.7%     159,234    123,617  28.8%
                      ------     ------             -------    -------

     income (loss)  (232,646)   354,368 (165.7%)    377,194    574,667 (34.4%)
         margin        (6.9%)      9.4%                4.9%       8.0%
      Other income    17,492     26,094  (33.0%)     32,365     52,396 (38.2%)
                      ------     ------              ------     ------

    Net income
     (loss) before
     income taxes   (215,154)  $380,462 (156.6%)   $409,559   $627,063 (34.7%)
    Income taxes
     (benefit)    (1,800,026)       558          (1,780,654)     5,555
                  ----------        ---          ----------      -----
    Net income    $1,584,872   $379,904  317.2%  $2,190,213   $621,508 252.4%
                  ==========   ========          ==========   ========

      Net income
       per share
        Basic          $0.12      $0.03               $0.17      $0.05
                       =====      =====               =====      =====
        Diluted        $0.11      $0.03               $0.16      $0.05
                       =====      =====               =====      =====

        Basic     12,841,280 12,157,441          12,751,844 12,109,845
        Diluted   13,839,779 13,494,251          13,771,731 13,514,774

                           Consolidated Balance Sheets

                                                      12/31/2008  6/30/2008
                                                      ----------  ---------

    Current assets:
      Cash and cash equivalents                       $2,064,290 $2,035,219
      Restricted cash                                          -     10,010
      Accounts receivable, net                         1,133,015  1,183,975
      Inventory                                          830,640    580,861
      Prepaid and other assets                           343,638    359,894
      Deferred income taxes                               17,352          -
                                                          ------        ---
        Total current assets                           4,388,935  4,169,959
    Property and equipment, net                        1,809,641  1,375,657
    Deferred income taxes, net                         3,106,390          -
    Intangible assets, net                               152,932    130,702
                                                         -------    -------
        Total assets                                  $9,457,898 $5,676,318
                                                      ========== ==========

    Current liabilities:
      Accounts payable                                  $696,002   $778,423
      Accrued liabilities                                245,470    432,971
      Current portion of deferred revenue              1,134,994  1,063,016
                                                       ---------  ---------
        Total current liabilities                      2,076,466  2,274,410
    Long-term deferred revenue                           633,178    516,372
                                                         -------    -------
        Total liabilities                              2,709,644  2,790,782
    Stockholders' equity:
      Total stockholders' equity                       6,748,254  2,885,536
                                                       ---------  ---------
        Total liabilities and stockholders' equity    $9,457,898 $5,676,318
                                                      ========== ==========

              Supplemental Customer Billing and Revenue Information

                         Three-Months Ended December 31,
                              2008   % Total       2007    % Change
                              ----   -------       ----    --------
      Health Care        $1,709,000     52.7% $1,933,695     (11.6%)
      Retail                455,077     14.0%    315,115      44.4%
      Professional          313,157      9.7%    168,317      86.1%
      Hospitality           221,791      6.8%    306,779     (27.7%)
      Pharmaceutical        144,512      4.5%    491,157     (70.6%)
      Commercial            110,212      3.4%    160,137     (31.2%)
      Non-Mailable           92,972      2.9%    116,253     (20.0%)
      Agriculture            92,617      2.9%    173,694     (46.7%)
      Other                  36,634      1.1%     35,072       4.5%
      Government             65,647      2.0%     85,090     (22.8%)
                             ------      ---      ------     -----
        Subtotal          3,241,619    100.0%  3,785,309     (14.4%)
      GAAP Adjustment *     128,027              (34,507)    471.0%
                            -------              -------     -----
        Revenue Reported  3,369,646            3,750,802     (10.2%)
                          =========            =========     =====

                          Six-Months Ended December 31,
                              2008   % Total       2007    % Change
                              ----   -------       ----    --------
      Health Care        $3,615,697     45.7% $3,852,959      (6.2%)
      Retail              1,295,839     16.4%  1,000,551      29.5%
      Professional          561,598      7.1%    339,501      65.4%
      Hospitality           431,244      5.5%    670,014     (35.6%)
      Pharmaceutical      1,019,125     12.9%    498,342     104.5%
      Commercial            294,711      3.7%    276,246       6.7%
      Non-Mailable          223,325      2.8%    241,523      (7.5%)
      Agriculture           266,628      3.4%    266,998      (0.1%)
      Other                  74,789      0.9%     84,276     (11.3%)
      Government            120,797      1.5%    141,151     (14.4%)
                            -------      ---     -------     -----
        Subtotal          7,903,753    100.0%  7,371,561       7.2%
      GAAP Adjustment *    (264,571)            (229,647)     15.2%
                           --------             --------      ----
        Revenue Reported  7,639,182            7,141,914       7.0%
                          =========            =========       ===

    * Represents the net impact of the revenue recognition adjustments to
    arrive at reported GAAP revenue. Customer billings include all invoiced
    amounts for products shipped during the period reported. GAAP revenue
    includes customer billings as well as numerous adjustments necessary to
    reflect, (i) the deferral of a portion of current period sales and (ii)
    recognition of certain revenue associated with product returned for
    treatment and destruction. The difference between customer billings and
    GAAP revenue is reflected in the Company's balance sheet as deferred

SOURCE Sharps Compliance Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sharps Compliance Announces $40 Million U. S. Government Contract
2. Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009
3. Sharps Compliance Corp. Announces Results for Third Quarter of Fiscal Year 2008
4. Sharps Compliance Corp. Announces Appointment of Al Aladwani as its Senior Vice President of Operations
5. Sharps Compliance Corp. to Present at the RedChip Small-Cap Investor Conference in Scottsdale, Arizona
6. Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008
7. Sharps Compliance Corp. Announces New Senior Vice President of Sales and Marketing
8. Sharps Compliance Corp. Announces First Quarter Fiscal Year 2008 Conference Call and Webcast
9. New Website Offers Easy Access to Breaking HealthCare News and Regulatory Compliance Information
10. AMERIGROUP Names Finley Chief Compliance Officer
11. CAM Pharmacy Point of Sale Software Receives SIGIS Certification for IIAS Compliance
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... has been recognized once again for its stellar workplace culture with the company’s ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati ...
(Date:11/25/2015)... ... November 26, 2015 , ... ... European Union (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, ... (UNON) for the opening of the 5th African Network for Drugs and Diagnostics ...
(Date:11/25/2015)... Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... da Vinci surgical robot is being more and more widely heralded as a breakthrough ... assisted da Vinci method has over traditional laparoscopic surgery is that it can greatly ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug ... a new cutting edge recovery program that has been 50 years in the making. ... individuals with the purpose to free addicts from the symptoms and negative behaviors of ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy ... personal heating products business. Cozy Products explains what this means for business moving ... well with the Cozy Products business model: to sell personal heaters that reduce energy ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Nov. 25, 2015 AAIPharma Services Corp./Cambridge ... of at least $15.8  Million to expand its ... NC . The expansion will provide additional ... the growing demands of the pharmaceutical and biotechnology ... expansion will provide up to 40,000 square feet ...
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
Breaking Medicine Technology: